» Articles » PMID: 29644599

Long-term Effectiveness and Safety of Metreleptin in the Treatment of Patients with Generalized Lipodystrophy

Overview
Journal Endocrine
Specialty Endocrinology
Date 2018 Apr 13
PMID 29644599
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The purpose of this study is to summarize the effectiveness and safety of metreleptin in patients with congenital or acquired generalized lipodystrophy.

Methods: Patients (n = 66) aged ≥6 months had lipodystrophy, low circulating leptin, and ≥1 metabolic abnormality (diabetes mellitus, insulin resistance, or hypertriglyceridemia). Metreleptin dose (once or twice daily) was titrated to a mean dose of 0.10 mg/kg/day with a maximum of 0.24 mg/kg/day. Means and changes from baseline to month 12 were assessed for glycated hemoglobin (HbA1c), fasting triglycerides (TGs), and fasting plasma glucose (FPG). Additional assessments included the proportions of patients achieving target decreases in HbA1c or fasting TGs at months 4, 12, and 36, medication changes, and estimates of liver size. Treatment-emergent adverse events (TEAEs) were recorded.

Results: Significant mean reductions from baseline were seen at month 12 for HbA1c (-2.2%, n = 59) and FPG (-3.0 mmol/L, n = 59) and mean percent change in fasting TGs (-32.1%, n = 57) (all p ≤ 0.001). Reductions from baseline over time in these parameters were also significant at month 36 (all p < 0.001, n = 14). At month 4, 34.8% of patients had a ≥1% reduction in HbA1c and 62.5% had a ≥30% reduction in fasting TGs; at month 12, 80% of patients had a ≥1% decrease in HbA1c or ≥30% decrease in TGs, and 66% had a decrease of ≥2% in HbA1c or ≥40% decrease in TGs. Of those on medications, 41%, 22%, and 24% discontinued insulin, oral antidiabetic medications, or lipid-lowering medications, respectively. Mean decrease in liver volume at month 12 was 33.8% (p < 0.001, n = 12). Most TEAEs were of mild/moderate severity.

Conclusions: In patients with generalized lipodystrophy, long-term treatment with metreleptin was well tolerated and resulted in sustained improvements in hypertriglyceridemia, glycemic control, and liver volume.

Citing Articles

Acquired Generalized Lipodystrophy as an Adverse Event of Combined Immune Checkpoint Inhibitor Therapy.

Kennedy R, Macrohon C, David M, Lee M, Salama A, Shariff A JCEM Case Rep. 2025; 3(3):luaf023.

PMID: 39935494 PMC: 11809239. DOI: 10.1210/jcemcr/luaf023.


Assessment of aortomesenteric distance and mesenteric and retroperitoneal adipose tissue thickness in genetic forms of lipodystrophy.

Unal M, Uncuoglu F, Gungor Semiz G, Arayici M, Yener S, Altay C J Endocrinol Invest. 2024; 48(2):445-454.

PMID: 39352627 PMC: 11785631. DOI: 10.1007/s40618-024-02429-9.


Diagnosis, treatment and management of lipodystrophy: the physician perspective on the patient journey.

Patni N, Chard C, Araujo-Vilar D, Phillips H, Magee D, Akinci B Orphanet J Rare Dis. 2024; 19(1):263.

PMID: 38992753 PMC: 11241872. DOI: 10.1186/s13023-024-03245-3.


A rapid action plan to improve diagnosis and management of lipodystrophy syndromes.

Fourman L, Lima J, Simha V, Cappa M, Alyaarubi S, Montenegro Jr R Front Endocrinol (Lausanne). 2024; 15:1383318.

PMID: 38952397 PMC: 11215967. DOI: 10.3389/fendo.2024.1383318.


GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy.

Roumane A, Mcilroy G, Sommer N, Han W, Heisler L, Rochford J Front Endocrinol (Lausanne). 2024; 15:1379228.

PMID: 38745956 PMC: 11091257. DOI: 10.3389/fendo.2024.1379228.


References
1.
Kamran F, Rother K, Cochran E, Safar Zadeh E, Gorden P, Brown R . Consequences of stopping and restarting leptin in an adolescent with lipodystrophy. Horm Res Paediatr. 2012; 78(5-6):320-5. PMC: 3590018. DOI: 10.1159/000341398. View

2.
Christensen J, Lungu A, Cochran E, Collins M, Gafni R, Reynolds J . Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. J Clin Endocrinol Metab. 2014; 99(8):E1493-500. PMC: 4121033. DOI: 10.1210/jc.2014-1353. View

3.
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman J . Positional cloning of the mouse obese gene and its human homologue. Nature. 1994; 372(6505):425-32. DOI: 10.1038/372425a0. View

4.
Meehan C, Cochran E, Kassai A, Brown R, Gorden P . Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Expert Rev Clin Pharmacol. 2015; 9(1):59-68. PMC: 4931926. DOI: 10.1586/17512433.2016.1096772. View

5.
Vatier C, Fetita S, Boudou P, Tchankou C, Deville L, Riveline J . One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes. Diabetes Obes Metab. 2015; 18(7):693-7. DOI: 10.1111/dom.12606. View